Roxanne Lagano - Zoetis President
| ZTS Stock | USD 146.50 6.61 4.32% |
President
Ms. Roxanne Lagano is Executive Vice President, Chief Human Resources Officer and Communications of Zoetis Inc. Ms. Lagano has served as our Executive Vice President and Chief Human Resources Officer since November 2012 and was given responsibility for corporate communications in 2015. Prior to joining Zoetis, Ms. Lagano was Senior Vice President, Global Compensation, Benefits and Wellness for Pfizer. Ms. Lagano joined Pfizer in 1997 and held various positions, including Senior Director, Business Transactions, Pfizer Worldwide Human Resources. since 2020.
| Age | 59 |
| Tenure | 4 years |
| Address | 10 Sylvan Way, Parsippany, NJ, United States, 07054 |
| Phone | 973 822 7000 |
| Web | https://www.zoetis.com |
Latest Insider Transactions
| 2024-04-18 | Disposed of 923 shares @ 151.17 | View | |
| 2024-03-18 | Disposed of 923 shares @ 173.33 | View | |
| 2024-02-12 | Disposed of 363 shares @ 197.74 | View | |
| 2024-01-18 | Disposed of 923 shares @ 191.43 | View | |
| 2023-12-14 | Disposed of 2500 shares @ 200 | View | |
| 2023-11-17 | Disposed of 923 shares @ 177.46 | View | |
| 2023-10-18 | Disposed of 923 shares @ 172.92 | View | |
| 2023-09-18 | Disposed of 923 shares @ 179.58 | View | |
| 2023-09-01 | Disposed of 923 shares @ 192.97 | View |
Zoetis Management Efficiency
The company has Return on Asset of 0.1315 % which means that on every $100 spent on assets, it made $0.1315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4982 %, implying that it generated $0.4982 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Tangible Assets are likely to drop 0.12 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Craig Hopkinson | Alkermes Plc | 49 | |
| Mark Namchuk | Alkermes Plc | N/A | |
| Adrian Hepner | Eagle Pharmaceuticals | 56 | |
| Gordon Pugh | Alkermes Plc | 57 | |
| CTodd Nichols | Alkermes Plc | N/A | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Mark Stejbach | Alkermes Plc | 55 | |
| Halley Gilbert | Ironwood Pharmaceuticals | 48 | |
| Kelly MacDonald | Ironwood Pharmaceuticals | 34 | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| DavidAlexandre Gros | Neurocrine Biosciences | 43 | |
| Michael Landine | Alkermes Plc | 70 | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| Robert Janssen | Dynavax Technologies | 70 | |
| Shane Cooke | Alkermes Plc | 54 | |
| David Johnson | Dynavax Technologies | 56 | |
| Bill Aurora | Neurocrine Biosciences | N/A | |
| Elliot Ehrich | Alkermes Plc | 57 | |
| Christopher Wright | Ironwood Pharmaceuticals | N/A | |
| Mark Currie | Ironwood Pharmaceuticals | 63 | |
| David Gaffin | Alkermes Plc | 52 | |
Management Performance
Zoetis Inc Leadership Team
Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply | ||
| Steven Frank, Vice Relations | ||
| Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director | ||
| Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer | ||
| William Steere, Independent Director | ||
| Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations | ||
| Linda Rhodes, Independent Director | ||
| Timothy Bettington, Executive Vice President and President U.S. Operations | ||
| Ester Banque, Executive Operations | ||
| Frank DAmelio, Independent Director | ||
| Robert Scully, Independent Director | ||
| Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics | ||
| Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand | ||
| Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications | ||
| Sanjay Khosla, Independent Director | ||
| Paul Herendeen, CFO and Executive VP | ||
| William Price, VP Officer | ||
| Jamie Brannan, Executive Diagnostics | ||
| Catherine Knupp, Executive Vice President, President - Research and Development | ||
| Jeannette Astorga, Executive Officer | ||
| Michael McCallister, Non-Executive Independent Chairman of the Board | ||
| Paul Bisaro, Independent Director | ||
| Antoinette Leatherberry, Independent Director | ||
| Nick Ashton, Executive Supply | ||
| Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region | ||
| Willie Reed, Independent Director | ||
| William Dorsey, Vice Diagnostics | ||
| Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region | ||
| Rimma Driscoll, Commercial Strategy | ||
| Glenn David, Chief Financial Officer, Executive Vice President | ||
| Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development | ||
| Sandra Beaty, Executive Vice President - Corporate Affairs | ||
| Robert Kelly, Executive Vice President and President International Operations | ||
| J McFarland, Executive Vice President and Chief Medical Officer | ||
| Robert Polzer, Executive Vice President and Presidentident of Research and Development | ||
| William Doyle, Director | ||
| Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer | ||
| Gregory Norden, Independent Director | ||
| Louise Parent, Independent Director | ||
| Heidi Chen, Executive Vice President General Counsel, Corporate Secretary | ||
| Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses | ||
| Juan Alaix, Chief Executive Officer, Director |
Zoetis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 74.9 B | ||||
| Shares Outstanding | 456.95 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 95.60 % | ||||
| Number Of Shares Shorted | 3.65 M | ||||
| Price To Earning | 43.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zoetis Inc is a strong investment it is important to analyze Zoetis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zoetis' future performance. For an informed investment choice regarding Zoetis Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zoetis Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Zoetis Stock analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Zoetis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zoetis. If investors know Zoetis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zoetis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.164 | Dividend Share 1.5 | Earnings Share 5.07 | Revenue Per Share 18.527 | Quarterly Revenue Growth 0.085 |
The market value of Zoetis Inc is measured differently than its book value, which is the value of Zoetis that is recorded on the company's balance sheet. Investors also form their own opinion of Zoetis' value that differs from its market value or its book value, called intrinsic value, which is Zoetis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zoetis' market value can be influenced by many factors that don't directly affect Zoetis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zoetis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zoetis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.